| ** | Latin American Journal of Clinical Sciences and Medical Technology is an open access magazine. To read all published articles and materials you just need to register Registration is free of charge. Register now If you already have registered please Log In | ** |
Lat Am J Clin Sci Med Technol. 2020 Apr;2:43.
Received: April 20th, 2020.
Accepted: April 20th, 2020.
Published: April 24th, 2020.
Views: 800
Downloads: 16
| 1. | Noël F, Lima J. Pharmacological aspects and clues for the rational use of Chloroquine/Hydroxychloroquine facing the therapeutic challenges of COVID-19 pandemic. Lat Am J Clin Sci Med Technol [Internet]. 2020;2:28–34. Available from: http://www.lajclinsci.com/cuIS |
| 2. | Geary TG. Ivermectin 20 years on: Maturation of a wonder drug. Trends Parasitol [Internet]. 2005 Nov [cited 2020 Apr 21];21(11):530–2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16126457 |
| 3. | Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Apr;178:104787. |
| 4. | Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res [Internet]. 2020 Apr 21 [cited 2020 Apr 21];104805. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0166354220302199 |
| 5. | Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar 1;30(3):269–71. |
| 6. | BRASIL. Departamento de Ciência e Tecnologia. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Ministério da Saúde. Informe Diário de Evidências – COVID-19 (20 de abril de 2020). |
| 7. | Gamiño-Arroyo AE, Guerrero ML, McCarthy S, Ramírez-Venegas A, Llamosas-Gallardo B, Galido-Fraga A et al. Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. - PubMed - NCBI. Clin Infect Dis [Internet]. 2019 [cited 2020 Apr 21];69(11):1903–11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=Clin+Infect+Dis+2019%3B+69(11)%3A1903-1911 |
0000-0001-6813-1347)a.aInstituto de Ciências Biomédicas, Federal University of Rio de Janeiro.
Corresponding Author: , . Telephone number: ; e-mail: fnoel@pharma.ufrj.br
Sir,
As scientists, we have to be concerned with the ease drugs are being proposed to face the COVID-19 pandemic. Recurrently, non-specialized media have created high expectations of short-term therapeutic benefits, although they are only based on results from in vitro experiments, case reports or even personal experiences. As pharmacologists, we know that such results have to be confirmed in well-conducted clinical studies that support evidence-based medicine.1 Such studies involve much more pharmacology aspects than only the necessary preliminary in vitro studies, such as pharmacokinetics, the search for doses that can ensure the optimization of the risk-benefit balance and the assessment of the most appropriate time for the administration of the drug depending on the stage of the disease.
Unfortunately, such a situation sometimes is also engendered by some health professionals. As an example, we can cite the ivermectin case, a large spectrum macrocyclic lactone effective against many nematode species2, after the publication of a paper reporting its inhibitory effect on the replication of SARS-CoV-2 in cell culture.3 This paper received widespread attention on human and veterinary medical websites in the USA, which often referred to ivermectin as a potential cure for coronavirus infection so that the Editor-in-Chief of the journal had to publish a caution notice.4
In Brazil, such concerns also exist. The Brazilian Society for Pharmacology and Experimental Therapeutics (https://www.sbfte.org.br/nota-sbfte-sobre-covid-19/) publicly pointed out and emphasized the need for the rigorous application of the scientific method to avoid the population feels deceived, which could generate a feeling of mistrust regarding science as a whole.
The first example of a political declaration of too early optimism regarding a drug before consistent proofs of efficacy was the case of chloroquine/hydroxychloroquine, as already discussed in this journal.1 More recently, the Brazilian Minister of Sciences and Technology publicly announced the engagement of clinical trials with a cheap and available drug that could be repurposed for COVID-19 treatment. Very rapidly, the name of this drug was revealed, being nitazoxanide, a broad-spectrum anti-infective drug that has been shown to have in vitro effect on cells infected with the SARS-CoV-2 virus.5 Two clinical trials with this drug have been approved by the Brazilian National Research Ethics Commission (CONEP) and registered on April, 14th.6 Again, caution is necessary since translation from bench to bedside is not straightforward even more after the report that treatment with nitazoxanide did not reduce the duration of hospital stay in severe influenza-like illness.7
I have no conflict of interest.
All Rights Reserved® 2019
Latin American Journal of Clinical Sciences and Medical Technology,Continuous Publication • Responsible Editor: Gilberto Castañeda Hernández • Reservation of Exclusive Use Rights: 04-2019-062013242000-203; ISSN: 2683-2291; both granted by Instituto Nacional del Derecho de Autor. • Responsible for the last update of this issue, Web Master Hunahpú Velázquez Martínez.
Calle Profesor Miguel Serrano #8, Col. Del Valle, Alcaldía Benito Juárez, CP 03100, Ciudad de México, México. Telephone number: 55 5405 1396 • Last modified on August 28th, 2026.
All Rights Reserved® 2019
Continuous Publication • Responsible Editor: Gilberto Castañeda Hernández • Reservation of Exclusive Use Rights: 04-2019-062013242000-203; ISSN: 2683-2291; both granted by Instituto Nacional del Derecho de Autor. • Responsible for the last update of this issue, Web Master Hunahpú Velázquez Martínez.
Calle Profesor Miguel Serrano #8, Col. Del Valle, Alcaldía Benito Juárez, CP 03100, Ciudad de México, México. Telephone number: 55 5405 1396 • Last modified on August 28th, 2026.
Privacy Policy
Latin American Journal of Clinical Sciences
Latin American Journal of Clinical Sciences (Lat Am J Clin Sci Med Technol) is committed to protecting the privacy and personal data of authors, editors, readers, and other users who interact with its editorial and digital platforms. This privacy policy describes how we collect, use, store, and protect such information.
1. Data controller
Lat Am J Clin Sci Med Technol is responsible for the processing of personal data collected through its website, manuscript submission system, and other official publishing channels.2. Personal data we collect
Lat Am J Clin Sci Med Technol may collect and use internally (without sharing with third parties) the following personal data:- Full name
- Institutional affiliation
- ORCID (when the author provided)
- Professional and academic information
- Data associated with manuscript submission, peer review, and editorial processes
- IP address, cookies, and website navigation data
- Administrative information required for scientific publication
3. Purpose of data use
Personal data is used exclusively for the following purposes:- Management of the editorial process (submission, peer review, editorial decisions, and publication)
- Communication between authors, reviewers, and editors
- Indexing, dissemination, and academic archiving of published articles
- Compliance with ethical, legal, and regulatory standards
- Improving website performance and security
- Production of internal statistics on use and editorial performance
4. Legal basis for data use
The processing of personal data is based on:- The user's explicit consent
- The need to execute the editorial and contractual process
- The legitimate interest of Lat Am J Clin Sci Med Technol in the dissemination of scientific knowledge
- Compliance with applicable legal and ethical obligations
5. Confidentiality and peer review
Lat Am J Clin Sci Med Technol guarantees confidentiality of submitted manuscripts and the peer review process. The data of authors and reviewers will not be disclosed outside the editorial scope, except when strictly necessary for scientific publication or by legal requirement.6. Data sharing
Some data may be shared only with:- Editorial management platforms
- Indexing and registration services (e.g., Crossref, PubMed, DOAJ)
- Technology providers needed for website operation
- Competent authorities, where there is a legal obligation
7. Data retention
The personal data will be kept:- For the time required for editorial and publication management
- As long as the article remains published as part of the academic archive
- As required by applicable legal or regulatory obligations
8. Information security
Lat Am J Clin Sci Med Technol implements reasonable technical and organisational measures to protect personal data against unauthorised access, loss, alteration or improper disclosure.9. Rights of the owners of the information
Users are entitled to:- Access to their personal data
- Request correction of incorrect information
- Request the deletion of their data, when legally possible
- Object to the processing of their data
- Request the limitation or portability of data